Paris, France (13 November 2025) – EssilorLuxottica announces its membership in the Collaborative Community of Ophthalmic Innovation (CCOI), a global catalyst uniting patients, clinicians, researchers, regulators, and industry to accelerate breakthrough science into real-world solutions – unlocking the eye’s potential to advance both ophthalmology and the broader healthcare ecosystem.

Joining the CCOI highlights EssilorLuxottica’s long-standing commitment to patient-centric innovation across diagnostics, treatment and data-driven ophthalmology. Through multi-stakeholder collaboration, scientific rigor and consensus-building, the Group will contribute optical engineering excellence, digital health capabilities and global scale to help translate emerging science into meaningful patient outcomes.

“Joining the Community at the highest level of industry participation reflects our dedication to advancing ophthalmic science through industry collaboration. By integrating our capabilities with the Community’s collective knowledge, we aim to accelerate translational research and clinical breakthroughs that will redefine how eye diseases are detected, managed, and ultimately prevented. We are also proud to bring capabilities from across our Group, including Heidelberg Engineering, whose decades of leadership in imaging and data science will help drive the next generation of evidence-based ophthalmic innovation”, commented Dr. Norbert Gorny, Chief Scientific Officer at EssilorLuxottica.

“We are honored to welcome EssilorLuxottica as a Vision Architect of the Collaborative Community on Ophthalmic Innovation,” said Dr. Malvina Eydelman, CEO of CCOI. “Through this leadership role, EssilorLuxottica will help shape global standards and scientific frameworks by driving CCOI’s Endpoints Consensus Workshops and global standards initiatives – advancing a unified, patient-centered foundation for ophthalmic innovation worldwide.”

Aligned with its open and collaborative approach, the Group will engage in the CCOI’s key workstreams, including myopia, oculomics, AI, age-related macular degeneration and glaucoma, applying its scientific and technological strengths to advance global eye health.

DOWNLOAD THE PRESS RELEASE